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Testosterone is known to act differentially on skeletal muscle from different regions. 
Two genes likely to mediate the testosterone effect are insulin-like growth factor-I 
(IGF-I), an important growth regulator acting in an autocrine and paracrine way, and 
androgen receptor (AR), as receptor density could account for differential muscle 
growth. Another muscle-specific gene that may play a role in differential muscle 
growth is myostatin, a member of the transforming growth factor-beta superfamily, 
shown to be a negative regulator of skeletal muscle mass. The objective of this study 
was to quantify and compare the expression of these three genes in two different 
skeletal muscles in sheep. East Friesian x Dorset sired ram lambs born from Dorset 
ewes were used in a 2 x 4 factorial experiment. Eighteen sets of twins were assigned to 
four age groups corresponding to 77, 105, 133 and 161 days of age and one individual 
from each set was castrated at birth. Total RNA was extracted from samples of 
semitendinosus (ST) and splenius (SP) muscles collected at the time of slaughter. 
Insulin-like growth factor I mRNA was measured using competitive reverse-
transcription-polymerase chain reaction (RT-PCR). Androgen receptor and MSTN 
mRNA were measured by ribonuclease protection assay (RPA) with standard curves. 
Splenius muscle weight was greater than semitendinosus muscle weight in rams 
compared with wethers at 105, 133 and 161 days (p = 0.05, p = 0.04 and p = 0.02). 
The difference in IGF-I mRNA levels between the two muscles was higher in rams 
than in wethers at 133 and 161 days (p < 0.05) and the difference in AR mRNA levels 
was higher in rams than in wethers at 105, 133 and 161 days (p < 0.05), with higher  
expression in the SP. No difference was found in the MSTN mRNA level between the 
two muscles in rams and wethers at any age. These results show that locally produced 
IGF-I and the regulation of AR expression are important for sexually dimorphic 
muscle growth patterns.
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 1 
CHAPTER I 
INTRODUCTION 
 
Male animals are generally larger than females (Glucksmann 1974) and have 
more muscle, especially in the neck and the forequarters. Different growth rates for 
individual muscles or muscle groups are of special interest for meat production as 
improving muscle growth of meat producing animals has been a major endeavor of 
farmers and agricultural scientists. Alterations in muscle growth rate are commonly 
attributed to changes in function and to hereditary tendencies of serial development as 
well as to the influence of bone growth on muscle growth (Stewart 1972, Berg & 
Butterfield 1976, Taylor 1980, Dickson et al. 1991). Besides these basic 
developmental changes affecting muscle growth, a variety of other factors such as sex, 
rate of growth, loss and gain of body weight or deposition of fat within the 
musculature modifies the muscle growth pattern. 
Sexual dimorphism in muscle growth relates to the protein anabolic effect of 
testicular hormones. It was shown (Arnold et al. 1997) that splenius muscle of the 
neck in rams and in wethers implanted with testosterone was heavier and had a 
biphasic growth pattern when compared to the single phase of growth of the same 
muscle in wethers. These results confirm the hypothesis that testosterone is implicated 
in the increased neck muscle mass in sexually mature rams. Among serum insulin-like 
growth factor I (IGF-I), growth hormone (GH) and cortisol, only IGF-I concentrations 
increased in response to the testosterone treatment (Arnold et al. 1996). Subsequently, 
the expression of IGF-I, androgen receptor (AR) and myostatin (MSTN) genes was 
measured in both splenius (sexually dimorphic) and semitendinosus (not sexually 
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dimorphic) muscles in rams (Mateescu & Thonney 2002) and it was suggested that the 
increased splenius muscle mass of the neck associated with sexual maturity of rams is 
mediated by an increase in mRNA of the IGF-I and AR genes.  
Regulatory factors that contribute to differential growth are most likely located 
in the respective tissues since alterations in circulating concentrations of hormones or 
growth factors as well as in blood supply cannot explain why certain tissues grow 
faster or slower than the body in total.  Possible levels of regulation for the mediation 
of different muscle growth rates include: 
z  local synthesis of growth factors acting in a paracrine or autocrine manner; 
z  sensitivity of the tissue to growth regulating hormones, i.e. the density and 
the affinity of the respective receptors; 
z  local synthesis of specific binding proteins, which may increase or inhibit 
the action of the relevant growth factors. 
At least two of these levels of regulation are associated with testosterone.   
Testosterone could exert an effect on muscle growth through the IGF-I axes. Locally 
produced IGF-I is an important growth regulator acting in an autocrine and paracrine 
manner (Weimann & Kiess 1990), but different muscles may posses different IGF-I 
sensitivities (Boge et al. 1995) and (or) IGF-I synthesis rates (Thissen et al. 1994, 
Frost et al. 1997, Pfaffl et al. 1998b) and, therefore, may exhibit different growth 
rates. Second, testosterone action is mediated by the androgen receptor (AR), which 
transduces the steroid signal within cells. Therefore, receptor density could account for 
the relatively higher sensitivity to testicular steroids in the neck muscles (Sauerwein & 
Meyer 1989).  
In addition to the effect of testosterone on muscle growth, muscle-specific 
genes could be differentially expressed in certain muscles. One of these is myostatin, a 
gene known to inhibit muscle development.  3 
 
In a previous study we showed that there is an increas in IGF-I and AR gene 
expression in the splenius muscle, but one question that the experiment could not 
address was if the increase was a result of testosterone. Therefore, the objective of this 
project was to analyze the role of IGF-I, AR and myostatin genes in the differential 
growth phenomena in response to testosterone. The approach was to quantify IGF-I, 
AR and myostatin mRNA expression and to assess if mRNA expression of these 
genes were different in splenius (sexually dimorphic) and semitendinosus (not 
sexually dimorphic) muscles in rams and wethers of different ages. 
1.1 Characterization and expression of the IGF-I gene 
The IGF-I gene is composed of at least six exons (Wong et al. 1989, Dickson 
et al. 1991, Froesch et al. 1996) and encodes a 70 amino acid polypeptide. In sheep, 
exon W is located upstream of exon 1 (Ohlsen et al. 1993). Exon W, 1 and 2 are the 
leader exons differentially spliced to exon 3 to produce class W, class 1 and class 2 
transcripts, respectively. Exon 3 and exon 4 encode the mature IGF-I peptide, while 
exon 5 does not seem to be present in sheep transcripts (Wong et al. 1989, Dickson et 
al. 1991, Pell et al. 1993, Hasty et al. 1993, Ohlsen et al. 1994).  The IGF-I gene 
organization in sheep is depicted in Figure 1.  
Class W, 1, and 2 transcripts are all found in fetal and adult sheep tissues 
(Ohlsen et al. 1994). Class 1 is the most abundant of these transcripts except for liver 
tissue in adult animals, where class 2 transcripts are the highest. In sheep muscle, 
 IGF-I gene expression consisted mainly of class 1 transcripts (Pell et al. 1993).  
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Figure 1. The organization of ovine IGF-I gene 
 
1.2 IGF-I and its biological functions 
Insulin-like growth factor I, a member of the family of insulin-related peptides, 
is a widely distributed trophic hormone capable of mediating autocrine, paracrine or 
endocrine effects. Insulin-like growth factor I was originally referred to as 
“somatomedin” to reflect its expression in response to growth hormone (GH) 
stimulation and its ability to mediate some of the growth-promoting effects of GH. 
Insulin-like growth factor I is structurally highly related to insulin (49% peptide 
identity) but, unlike insulin, is not cleaved during processing (Van den Brande 1994). 
Insulin-like growth factor I plays important roles in both embryonic and post-natal 
Figure 1. 
a) The organization of ovine IGF-I gene. (Wong et al. 1989) 
b) Predicted arrangement of exons in ovine IGF-I mRNA transcripts. Exons W, 1 
and 2 are alternatively spliced into exon 3 and generate transcripts W, 1 and 2.  
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mammalian growth (Froesch et al. 1985, Jones & Clemmons 1995, Liu & Leroith 
1999). Early studies compared the metabolic effect of IGF-I and insulin on muscle, 
including stimulation of protein metabolism, glucose transport, and glycogen and 
triglyceride synthesis (Hill et al. 1986, Harper et al. 1987, Roeder et al. 1988, Frost et 
al. 2003). More recently, research has shifted to the role of IGF-I in myogenesis and 
differentiation and in response to senescence, physical injury, and disease states 
(Florini et al. 1996, Le Roith et al. 1997, Le Roith 1999, Menetrey et al. 2000).  
Transgenic mice overexpressing IGF-I have enhanced body growth with an 
increase in muscle mass (Mathews et al. 1988). In contrast, mice deficient in IGF-I are 
significantly smaller than their litter mates, have a severe muscular dystrophy, and 
most (> 95%) die at birth (Powell-Braxton et al. 1993, Liu et al. 1998). Specifically, 
the IGF-I-deficient heterozygotes were 10 to 20% smaller in total body size and in the 
size of individual organs, although these organs were histologically normal. Insulin-
like growth factor I-deficient homozygotes were dead at birth, their body weight was  
< 60% of their wild type siblings, and their lungs were not inflated (Powell-Braxton et 
al. 1993). It is evident that in these animal models IGF-I plays a fundamental role in 
muscle maturation and in the development of muscle mass. Although 75% of 
circulating IGF-I is liver-derived, normal growth and development are possible even 
in the absence of liver IGF-I production (Yakar et al. 1999, Sjogren et al. 1999) 
suggesting that locally produced IGF-I is sufficient for normal growth and 
development. Furthermore, targeted deletion of the acid-labile subunit gene, which 
also results in a large (60%) reduction in circulating IGF-I levels, is associated with 
only minor effects on growth rate and no discernable effects on glucose metabolism 
(Ueki et al. 2000). A major question that still remains to be answered, however, is why 
the liver produces an output sufficient to maintain such high levels of IGF-I in the 
circulation.  6 
 
Although growth factors, in general, inhibit the differentiation of skeletal 
muscle cells, IGF-I and IGF-II are unique in that they are the only known mitogens 
with opposing, time-dependent actions in skeletal myoblasts: initially, IGF-I induces 
proliferation and inhibits differentiation; subsequently, IGF-I promotes cell cycle exit 
and stimulates differentiation (Rosenthal & Cheng 1995, Adi et al. 2000). These 
opposing effects of IGF-I on myogenic differentiation are mediated, at least in part, by 
early inhibition and subsequent stimulation of the gene expression of myogenin 
(Rosenthal & Cheng 1995, Adi et al. 2000), a member of the MyoD family of skeletal 
muscle-specific transcription factors essential for myogenic differentiation 
(Nabeshima et al. 1993, Yun & Wold 1996, Samuel et al. 1999).   
IGF-I was shown to play an important role in the growth and regeneration of 
peripheral nerves and skeletal muscle, and it has been investigated as a treatment for 
neuromuscular disorders (Cheng et al. 1996) and muscle regeneration following injury 
(Menetrey et al. 2000). Treatment with exogenous IGF-I protein reduces muscle 
degeneration and atrophy in dystrophic mice (de Luca et al. 1999). Insulin-like growth 
factor I is also a potential angiogenic factor and inhibits vessel constriction, via 
stimulation of nitric oxide (Walsh et al. 1996, Miele et al. 2000, Akeno et al. 2002).   
1.2.1 IGF-I gene expression 
The IGF-I gene is expressed in many tissues, but liver and to a lesser extent 
bone, are the primarily sources of circulating IGF-I (Jones & Clemmons 1995). 
Several studies showed that IGF-I can be produced by skeletal muscle, although it is 
only found at low levels in normal, mature animals (Isgaard 1992, McGuire et al. 
1992, Daughaday 2000).  7 
 
1.2.2 IGF-I binding proteins 
In all extracellular tissues, IGF-I is bound to six well characterized binding 
proteins (IGFBPs) (Jones & Clemmons 1995, Firth & Baxter 2002). The IGFBPs are 
widely expressed in adult tissues but there is considerable variation in the type and 
extend of binding protein expressed. They each have different roles and their function 
may be cell/tissue dependent and at least some of them have IGF-I independent 
functions. These circulating IGFBPs act as carrier proteins, transporting IGF-I out of 
the circulation to the target tissues and prolonging the half-life of IGF-I by protecting 
it from proteolytic degradation. The IGFBPs function not only as carrier proteins for 
IGF-I in circulation, but also as modulators of IGF-I action (Clemmons et al. 1995). 
Most IGFBPs can either inhibit or potentiate IGF-stimulated actions, depending on 
cell type and incubation conditions. Evidence from in vitro studies suggests that 
IGFBP-2, -4, and -6 largely inhibit IGF-I action, IGFBP-5 enhances its action and 
IGFBP-1 and -3 can be either inhibitory or stimulatory (Murphy 1998).  
More than 70% of circulating IGF-I is carried in a trimeric complex composed 
of IGFBP-3, the largest molecular weight IGFBP, and a liver-derived glycoprotein 
known as the acid-labile subunit (ALS) (Hwa et al. 1999). All three components of the 
trimeric complex are induced by growth hormone (GH) and therefore are affected by 
states of GH deficiency or excess (Delhanty & Baxter 1997). IGFBP-3 was the first 
IGFBP identified as being present in the ternary complex but recent data suggest that 
IGFBP-5 is also capable of forming a complex with IGF-I and ALS (Twigg et al. 
2000).  8 
 
1.2.3 IGF-I receptor 
While IGF-I can bind under certain conditions to the IGF-II receptor, the 
insulin receptor and hybrid receptors, the actions of IGF-I as a potent mitogen, anti-
apoptotic factor and modulator of differentiation are mediated mainly through the 
IGF-I receptor (Jones & Clemmons 1995). Gene knockout studies revealed that the 
IGF-I receptor mediates the cellular responses of both IGF-I and IGF-II. The IGF-I 
receptor is a member of the tyrosine kinase growth factor receptor family that becomes 
activated upon ligand binding. Binding of IGF-I to the IGF-I receptor activates the 
intracellular tyrosine kinase domain, resulting in receptor autophosphorylation. This 
autophosphorylation allows enhanced binding of the insulin receptor substrate (IRS) 
proteins-1 and -2 and their subsequent tyrosine phosphorylation by the IGF-I receptor 
(Butler et al. 1998). IRS-1 signaling is necessary to the developmental myogenic 
effects of IGF-I. In mice with transgenic deletion of both IRS-1 alleles, constitutive 
overexpression of IGF-I results in rescue of normal organ development (e.g., kidney 
and heart), but is unable to produce normal growth of gastrocnemius muscle (Pete et 
al. 1999). Phosphotyrosines on IRS proteins act as docking sites for proteins 
containing Src homology-2 (SH2) domain-containing proteins which in the end results 
in downstream activation of the mitogen-activated protein kinases (MAPKs) and 
activation of phosphatidylinositol 3-kinase (PI3K) (De Meyts et al. 1994, De Meyts 
2002).  
IGF-I receptor plays a critical role in myoblast proliferation and differentiation. 
Among known muscle factors, IGF-I is unique in its ability to stimulate both myoblast 
proliferation and terminal differentiation to postmitotic myotubes (Figure 2). 
Activation of MAPKs is required for developmental IGF-I receptor-dependent 
mitogenesis (Coolican et al. 1997). By contrast, PI3K signaling mediates three crucial 9 
 
effects of IGF-I on muscle: fusion of myoblasts into myotubes, anabolic effects on 
protein and glucose uptake, and resistance to programmed cell death, or apoptosis 
(Kaliman et al. 1998).  
During post-natal growth it was shown that the binding capacity of IGF-I 
receptor changes and the pattern of receptor abundance and sensitivity to nutritional 
stress differs between skeletal muscles and cell types within skeletal muscle (Oldham 
et al. 1996). In rat muscle, cell surface IGF-I receptor expression drops by 80% 
between infancy and young adulthood with a subsequent decrease of 10 to 60% during 
senescence (Dardevet et al. 1994, Willis et al. 1997). 
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Figure 2. Intracellular signaling pathways for IGF-I 
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Figure 2. Intracellular signaling pathways following cell surface type I IGF 
receptor (IGF-I receptor) by IGF-I. Access of IGF-I to IGF-I receptor is mediated by 
IGFBPs. IGF-I binds to the extracellular subunit of IGF-I receptor, inducing 
autophosphorylation of the transmembrane subunit. Downstream signaling diverges 
through activation of either the mitogen-activated protein kinase (MAPK) cascade or 
phosphatydilinositol3-kinase (PI3K). MAPKs mediate the proliferative effects of 
IGF-I, while the consequences of PI3K signaling (listed) are more diverse. 11 
 
1.2.4 IGF-I regulation 
IGF-I activity is regulated in a complex manner. Circulating IGF-I 
concentrations are very sensitive to GH (Coleman et al. 1994, Oldham et al. 1996) and 
nutritional status (Rivero et al. 1995, Wilson et al. 1995, Pfaffl et al. 1998b). GH and 
nutrition are also two important regulators of IGF-I mRNA (Florini & Ewton 1992, 
Coleman et al. 1994). 
Liver may be the most GH-responsive tissue for IGF-I production and IGF-I 
gene expression, while most non-hepatic tissues do not show an increase in IGF-I 
message in response to GH (Duguay et al. 1994, Rivero et al. 1995, Oldham et al. 
1996). Pell et al. (1993) found that muscle IGF-I mRNA in sheep was insensitive to 
GH treatment as well as nutritional status. Similarly, treatment of pigs with porcine 
GH increased IGF-I mRNA levels in liver and adipose tissue, but not in skeletal 
muscle, although there was a substantial increase in muscle growth (Oldham et al. 
1996). In another species of farm animals, cattle, there was a similar lack of 
correlation between GH levels, growth, and muscle IGF-I mRNA levels (Duguay et al. 
1994). Wilson et al. (1995) observed that GH administration increased muscle IGF-I 
expression but he also suggested that muscle IGF-I mRNA can be produced in a GH-
independent manner. Thus it seems very clear that IGF-I gene expression can occur in 
muscle without stimulation by GH. In addition to GH and nutritional status, other 
factors like hormonal, tissue-specific and developmental factors, all modulate IGF-I 
gene expression (Pell et al. 1993). 
Testosterone has been implicated in the increased levels of IGF-I responsible 
for growth rate and body composition differences among intact males, castrated males 
and females (Ford & Llindt 1989). Increased muscle growth due to testosterone is 
caused in part by increasing the level of circulating IGF-I independent of GH 12 
 
concentrations (Arnold et al. 1996). Steers receiving steroid hormone implants had 
increased circulating IGF-I concentrations compared with nonimplanted steers and the 
longissimus and semimembranosus muscles of implanted steers showed an increase in 
IGF-I mRNA levels compared with the same muscle in the nonimplanted steers 
(Pampusch et al. 2003, White et al. 2003).    
Circulating IGF-I and IGF-I binding protein concentrations are increased in 
association with increasing levels of energy or protein intake (Hannon et al. 1991). 
Fasting alters muscle metabolism, exhausts glycogen stores, converts muscle to fatty 
acid metabolism, and ultimately forces protein degradation to fuel gluconeogenesis. 
Studies showed that IGF-I mRNA levels in the liver fall to less than 40% of control in 
rats after 30 hours of fasting (Clemmons & Underwood 1991) and other studies 
reported that fasting caused a decrease in muscle IGF-I mRNA levels in pigs (Emler & 
Schalch 1987). Insulin-like growth factor I mRNA and serum IGF-I decrease during 
acute and chronic fasting and rebound with refeeding (Lewis et al. 1997). Chronic 
malnourishment also lowers the serum IGF-I in rats and humans (Beaune et al. 1997, 
Gautsch et al. 1998). In sheep, circulating levels of IGF-I in plasma are regulated by 
nutrition (Oldham et al. 1999); however, the expression of IGF-I in skeletal muscle is 
relatively insensitive to short-term fasting (Oldham et al. 1996).  
The effect of testosterone on muscle IGF-I mRNA while holding diet, 
genotype and other factors constant was examined in this experiment. 
 
1.3 Testosterone, androgen receptor and muscle growth. 
Testosterone is a naturally occurring steroid that is synthesized primarily by 
the Leydig cells of the testis (95%). It is also synthesized by the adrenal cortex, and a 
small amount is produced by the ovaries. Testosterone can be converted by aromatase 13 
 
to estradiol and by 5α-reductase to 5α-dihydrotestosterone. The actions of testosterone 
and its metabolites within target cells are transduced by the low-abundance 
intracellular androgen receptor. It has been generally accepted the existence of a single 
molecular species of androgen receptor that functions primarily as a transcription 
regulatory protein (Zhou et al. 1994), and in this context the diverse biologic effects of 
androgens are surprising. The biologic effects of androgens can be classified into two 
major categories, either androgenic or anabolic. Androgenic biological effects include 
stimulation of the male reproductive tract, external genitalia, and secondary male 
sexual characteristics. Anabolic biological effects are the stimulation of growth for 
many organs such as muscle, kidney, salivary glands, and liver.  
The androgen receptor is a member of the superfamily of nuclear transcription 
factors that mediate the action of steroid hormones. When activated by ligand binding, 
these transcription factors bind to specific DNA sequences on target genes, referred to 
as hormone response elements, and regulate the transcriptional activity of those genes. 
The receptor proteins are modular in nature and contain three common domains: a 
highly conserved central domain that is responsible for DNA binding, a variable  
N-terminal region that is involved in transcriptional activation, and a C-terminal 
domain that binds ligand. Specific regions within these domains that vary between 
receptors are involved in nuclear translocation, dimerization, phosphorylation, and 
interaction with accessory factors.  
The human androgen receptor gene is located on the X chromosome and 
contains 8 exons, with a total length of 90 kb (Kuiper et al. 1989, Lubahn et al. 1989, 
Marcelli et al. 1990, Zhou et al. 1994) (Figure 3). The large first exon encodes the 
entire N-terminal domain. The small second and third exons separately encode the two 
DNA-binding zinc fingers that comprise the DNA-binding domain. The fourth exon 
encodes the hinge region that contains an important ligand-dependent nuclear 14 
 
localization signal. The remaining four exons encode the hormone-binding domain 
(Zhou et al. 1994). 
Androgen receptors are nuclear proteins that are activated by ligand binding 
(Marcelli et al. 1990). This initiates a complex cascade of events that include a 
conformation change, phosphorylation, dimerization, DNA binding of zinc fingers to 
androgen response elements, and interaction with accessory factors, other transcription 
factors, and RNA polymerase to alter the transcriptional activity of a specific gene 
(Poujol et al. 2000).  
Unliganded androgen receptors are primarily localized to the cell nucleus, and 
androgens diffuse into the nucleus, where they bind to available receptors. Androgen 
binding to a receptor induces an allosteric conformational change of the protein that  
results in hormone-dependent, DNA-independent phosphorylation of the receptor at 
several sites and dissociation from associated factors (heat shock proteins). This 
dissociation allows the androgen receptor to dimerize, which is essential for binding to 
androgen response elements (Prins 2000). Due to specific androgen-induced 15 
 
 
Figure 3. Organization of human AR gene and protein 
conformational changes, the zinc fingers in the DNA-binding domain are available to 
associate with specific androgen response elements on regulated genes (Mangelsdorf 
et al. 1995).  
In addition to their virilizing effects in the reproductive tracts of males, 
androgens have anabolic effects in some skeletal muscles. In adult animals, castration 
produces atrophy of the rat levator ani and bulbocavernosus muscles, frog flexor carpi 
radialis and flexor carpi centralis muscles, and several guinea pig muscles, such as the 
sternomastoid, spinotrapezius, and latissimus dorsi muscles, whereas the 
readministration of androgenic hormones to castrated animals results in normal growth 
of these muscles (Kochakian & Tillotson 1957, Thibert 1986, Rand & Breedlove 
1992, Celotti & Negri 1992). Furthermore, Krieg et al. (1977) have also reported that 
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Figure 3. Genomic organization of the human androgen receptor 
gene and functional domain structure of the androgen receptor protein. 
The androgen receptor gene has been mapped to the long arm of the X-
chromosome. The androgen receptor protein is encoded by eight exons 
and consists of several distinct functional domains (DNA binding domain, 
ligand-binding domain). 16 
 
the number of ARs varies among skeletal muscles, which may explain regional 
differences in the physiological response to androgen administration.   
Testosterone stimulates muscle growth by affecting the rate of protein 
synthesis, protein breakdown and the net gain or loss of muscle protein (Wong et al. 
1993). When testosterone increases muscle protein synthesis, intramuscular mRNA 
concentrations of IGF-I are increased and concentrations of the inhibitory IGF binding 
protein 4 are decreased (Rooyackers & Nair 1997). The response to testosterone 
differs among muscle groups and this differential response may be explained by the 
variation of AR number among skeletal muscles (Urban 1999). Thus, sexual 
dimorphism can be explained partly by higher androgen sensitivities in muscles with 
pronounced growth under androgen stimulation (Sauerwein & Meyer 1989). A recent 
study in cattle showed that androgen receptor mRNA concentrations in muscles with 
different fiber type compositions and growth impetus is positively related to the 
individual growth patterns (Brandstetter et al. 2000).  
1.4 Myostatin and the control of skeletal muscle mass  
  Myostatin, a member of the TGF-β superfamily also known as growth and 
differentiation factor-8 (GDF-8), is specifically expressed in muscle and is a key 
regulator of skeletal muscle development and growth. Although myostatin does not 
appear to be essential for either viability or fertility, its sequence is remarkably well  
conserved in animals, ranging from fish to birds and mammals, suggesting that the 
biological function of myostatin has been conserved throughout the animal kingdom 
(Brandstetter et al. 2000). The human myostatin gene comprises 3 exons and 2 introns 
and encodes for a 375-aa precursor protein (McPherron & Lee 1997) which contains a 
hydrophobic N terminus that acts as a secretory signal and a conserved domain that is 
important for proteolytic processing (McPherron et al. 1997, Thomas et al. 2000, 17 
 
Sharma et al. 2001). Cleavage of the protein gives rise to an N-terminal latency 
associated peptide (LAP) noncovalently attached to the C-terminal mature signaling 
peptide, which varies in size from 12.5 to 30 kDa, depending on species and 
posttranslational modifications (Gonzalez-Cadavid et al. 1998, Thomas et al. 2000, 
Lee & McPherron 2001, Taylor et al. 2001). The mature signaling peptide binds to its 
receptor, suggested to be activin type II receptor, to elicit its biological functions (Lee 
& McPherron 2001).  
Myostatin null mice generated by gene targeting showed a dramatic and 
widespread increase in skeletal muscle mass. Individual muscles in myostatin null 
mice weighed 2- to 3-fold more than those of wild-type mice, primarily due to an 
increase in the number of muscle fibers (hyperplasia) and an increase in fiber diameter 
(hypertrophy) (McPherron et al. 1997). In addition, myostatin knockout mice 
accumulate less fat than their wild type littermates (Lin et al. 2002, McPherron & Lee 
2002), which may be a secondary consequence of increased muscle mass since a 
similar effect is seen in other genetic models of muscle hypertrophy (Sutrave et al. 
1990, Musaro et al. 2001). Aside from having increased muscle and decreased fat, the 
myostatin knockout mice appear normal and healthy. Furthermore, the "double-
muscle" phenotypes of three breeds of cattle (Belgian Blue, Piedmontese (Grobet et al. 
1997) and Asturiana de los Valles (Dunner et al. 1997)) have been linked to nucleotide 
deletions, transitions, or transversions within the coding region of the myostatin gene. 
Belgian Blue and Piemontese double-muscled cattle have a 15 to 30% increase in 
skeletal muscle mass, in addition to higher birth weights and also lower fat and bone 
percentages compared to non-double muscled animals. Also, other breeds of cattle that 
are characterized by increased muscle mass (double muscling) have mutations in the 
myostatin coding sequence (Kambadur et al. 1997, Brandstetter et al. 2000). These 
mutations likely compromise the biological activity of the protein, which leads to 18 
 
increased muscle via hyperplasia and hypertrophy. The inheritance of double muscling 
in Belgian Blue cattle has been identified as a monogenic autosomal segregation 
pattern (Hanset & Michaux 1985, Charlier et al. 1995). The muscular hypertrophy 
(mh) locus has been termed “partially recessive” because a single copy of the allele 
can have some effect, although the full double-muscled phenotype requires the cattle 
to be homozygous. Gene mapping (Charlier et al. 1995) of the Belgian Blue cattle 
localized the mh gene to the centromeric end of the bovine chromosome 2 linkage 
group. The myostatin gene has been mapped to the same interval as the mh locus by 
genetic linkage (Smith et al. 1997) indicating that the myostatin gene and the muscular 
hypertrophy gene are one and the same. 
Initial studies from myostatin null mice and from double-muscled cattle breeds 
indicated that lack of myostatin activity during embryonic development causes growth 
of muscle tissue but there was no evidence that loss of myostatin activity during adult 
life has a similar effect. This question was addressed recently when Zimmers et al. 
(2002) showed that injection of high levels of myostatin into the thighs of adult mice 
produced, on average, 33% of total body weight loss. Part of this loss was due to a 
global decline in skeletal muscle mass and a near-total loss of adipose tissue. In 
contrast, inhibition of myostatin in adult mice for as little as 2 to 4 weeks leads to an 
increase in skeletal muscle size (Whittemore et al. 2003, Grobet et al. 2003). The 
increase in muscle mass, which varied from 13 to 30% was highly reproducible and 
occurred in both male and female mice of a variety of strains. The effect was observed 
in young adults as well as 24-week-old mice indicating that myostatin acts postnatally 
as a negative regulator of skeletal muscle growth. 
Male transgenic mice that overexpress myostatin protein selectively in the 
skeletal muscle had an 18 to 24% decrease of skeletal muscle mass and a decrease of 
muscle fiber size (Reisz-Porszasz et al. 2003). Female transgenic mice generated the 19 
 
same way did not differ from wild-type controls in either body weight or skeletal 
muscle mass even though the expression of myostatin mRNA and protein was 
increased in the skeletal muscle and was not lower compared with male mice.  
However, it was shown that increased body and muscle mass in male compared with 
female mice is associated with decreased expression of processed myostatin 
(McMahon et al. 2003). Interestingly, this decreased expression of processed 
myostatin is due to regulation after translation and, presumably, after secretion, 
because there was no difference in mRNA or in the LAP form of myostatin.  Although 
myostatin-null mice have two to three times more muscle mass than wild-type 
controls, males remain heavier than females (McPherron et al. 1997), implying that a 
reduction in myostatin does not regulate sexual dimorphism per se. Rather, it may 
enable anabolic factors like testosterone to enhance growth.  
Experiments with muscle atrophy and mechanically-induced hypertrophy were 
conducted to address the possible myostatin function in hypertrophy of fibers of fully 
differentiated muscle. Muscle atrophy caused by either hindlimb unloading (Carlson et 
al. 1999, Wehling et al. 2000, Reardon et al. 2001) or by denervation (Sakuma et al. 
2000) increased myostatin mRNA and protein level. These observations were 
supported by findings of Gonzales-Cadavid et al. (1998) who demonstrated that 
myostatin protein level increased in the muscle of HIV-infected patients undergoing 
weight loss. Myostatin protein level was also increased in mechanically-hypertrophied 
rat muscles.  
A series of reports have shown that myostatin mRNA and /or protein 
concentrations are increased in skeletal muscle in conditions associated with loss of 
muscle mass in postnatal life, such as sarcopenia of old age (Marcell et al. 2001, 
Schulte & Yarasheski 2001, Yarasheski et al. 2002) and disuse atrophy in men under 
prolonged bed rest (Zachwieja et al. 1999), after exposure to the microgravity 20 
 
environment of a spacelift (Lalani et al. 2000), and in association with glucocorticoid-
induced muscle loss (Lang et al. 2001, Ma et al. 2003). In contrast, recovery of muscle 
mass in the late stages of muscle regeneration is associated with a decrease of 
myostatin from the elevated levels detected immediately after injury (Kirk et al. 2000, 
Sakuma et al. 2000, Yamanouchi et al. 2000). 
Myostatin was shown to inhibit differentiation of adipocytes in vitro (Kim et 
al. 2001). Furthermore, loss of myostatin prevents an age-related increase in adipose 
tissue mass and partially attenuates the obese and diabetic phenotypes of two mouse 
models of obesity and diabetes, agouti lethal yellow (A
y) and obese (Lep 
ob/ob) 
(McPherron & Lee 2002).  
Myostatin was shown to function by controlling the proliferation of muscle 
precursor cells (Thomas et al. 2000). Myostatin promotes an increase in p21 
expression, a cyclin-dependent kinase inhibitor, and a decrease in Cdk2 protein and 
activity thus resulting in an accumulation of hypophosphorylated Rb protein. This in 
turn, leads to the sequestration of the E2F transcription factors, a family of proteins 
that are essential for the G1/S progression, which leads to the arrest of myoblasts in 
the G1-phase of cell cycle (Thomas et al. 2000). Thus, myoblast number and, hence, 
fiber number, following differentiation, is regulated (limited), suggesting that the 
increased number of myofibers in cattle and mice with heavy muscling is a result of 
deregulated myoblast proliferation caused by the absence of functional myostatin 
(Figure 3). The inhibitory effect of myostatin on myoblast proliferation has been 
shown to be reversible, as myoblasts maintained their ability to proliferate after 
myostatin was removed. Recently it was demonstrated that myostatin also negatively 
regulates myoblast differentiation (Langley et al. 2002). The degree of differentiation 
inhibition is dependent on the concentration of myostatin and cultured myoblasts 
readily differentiate upon removal of myostatin from the media. The inhibition of 21 
 
differentiation by myostatin was associated with decreased expression of the 
myogenic determining genes; myoD, myf5, myogenin, and p21. 
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Figure 4. A model for the role of myostatin in muscle growth 
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Figure 4. A model for the role of myostatin in muscle growth.  
A, during embryonic myogenesis, Myf-5 and MyoD specify cells to adopt the 
myoblast fate. Myoblasts then migrate and proliferate. In response to myostatin 
signaling, p21 is up-regulated, inhibiting cyclin-E·Cdk2 activity, which causes Rb 
inactivation and G1 arrest. Thus, myoblast number and, hence, fiber number, 
following differentiation, is regulated (limited).  
B, in the absence of functional myostatin, the signal for p21 up-regulation is lost and 
Rb remains in a hyperphosphorylated form, resulting in deregulated (increased) 
myoblast proliferation, which leads to increased fiber number.  
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CHAPTER II 
MATERIALS AND METHODS 
 
2.1 Animals  
East Friesian x Dorset sired ram lambs born from Dorset ewes were used in a 2 x 4 
factorial experiment. Twenty sets of twins were assigned randomly to four age groups 
corresponding to 77, 105, 133 and 161 days of age. The ages were chosen to start just 
before puberty (77 days of age) followed by 3 more ages at 4 week intervals. Within 
two days after birth, one of the twins was randomly selected and castrated using a 
rubber band. Four sets of twins were assigned for each of the first two age groups and 
6 sets for each of the last 2 age groups to ensure sufficient sets of twins were available 
for sampling at older ages. During the time of the experiment, one twin from each of 
two sets assigned to the 161-day sampling age were lost, therefore only 4 sets of twins 
were available for this age group. Lambs were fed the standard Cornell high energy 
barley based diet with 15% soy hulls added for digestible fiber, 14% soybean meal for 
protein and limestone, sheep salt, ammonium chloride and vitamin premix to satisfy 
the vitamin and mineral requirements. All animals were slaughtered in the Department 
of Animal Science abattoir within a 3-day range surrounding the assigned slaughter 
age. The animals were weighed before slaughter and the carcass weight was recorded 
after removal of the head, feat, skin and internal organs. Semitendinosus (ST) and 
splenius (SP) muscles were completely removed, trimmed of visible fat and weighed. 
Within 15 min after exsanguination, samples from both muscles were snap-frozen in 
liquid nitrogen, and stored at -70°C until they were subsequently assayed. 24 
 
2.2 RNA isolation 
Total RNA was isolated using the guanidine thiocyanate, acid 
phenol:chloroform procedure of Chomczynski and Sacchi (ToTALLY RNA™ Total 
RNA Isolation Kit, Ambion). Using a hand-held Tissue Tearor, about 140 mg muscle 
tissue were homogenized on ice in guanidinium-based lysis solution. Samples were 
extracted sequentially with Phenol:Chloroform:IAA (phenol, chloroform and isoamyl 
alcohol at a ratio of 25:24:1, pH 6.6) and Acid-Phenol:Chloroform (phenol and 
chloroform at a 5:1 ratio, pH 4.7). The RNA was then precipitated with isopropanol 
and the RNA pellet was resuspended in 60 to 70 µL of 1 mM sodium citrate, pH 6.4 
+/- 0.2 (The RNA Storage Solution, Ambion). RNA integrity was verified by 
inspection of the 28S and 18S rRNA bands using denaturing agarose gel 
electrophoresis and ethidium bromide stain.  
The concentration and purity of RNA in the final preparations was determined 
by diluting an aliquot of the preparation (1:50) in TE (10 mM Tris-HCl pH 8, 1 mM 
EDTA) and reading the absorbance in a spectrophotometer at 260 nm and 280 nm. 
The ratio of A260 to A280 values was a measure of RNA purity, and it should fall in 
the range of 1.8 to 2.1.  
2.3 RNase Protection Assay 
  2.3.1 Preparation of the AR, myostatin, GAPDH labeled antisense and 
unlabeled sense riboprobes. Full-length cDNA was generated from 500 ng of total 
ovine muscle RNA using a gene specific primer (Appendix Table 8) in the reverse 
transcription (Display THERMO-RT Kit). Total RNA, 1xRT buffer, 0.5 mM dNTPs 
(each of dATP, dGTP, dCTP, dTTP), 1 µM reverse primer, and display Terminator 
Mix were incubated for 40 min at 42°C followed by 10 min at 65°C. Specific regions 25 
 
were amplified from 1 µL of cDNA in 10 µL PCR amplification reactions (Appendix 
Table 8) using an Idaho Technologies Rapid Cycler. Each 10 µL reaction contained 
Idaho Technologies buffer (50 mM Tris, pH 8.3; 0.25 mM crystalline BSA; 2 mM or 4 
mM MgCl2; and sucrose), 0.4 U Taq DNA polymerase (Gibco BRL), 0.2 mM dNTPs 
(Promega Corporation) and 0.5 µM each primer.  The 453 bp myostatin PCR product 
containing parts of exons 1 (63 bp) and 3 (16 bp) and all of exon 2 (374 bp) and the 
556 bp GAPDH PCR product containing parts of the exons 6 (74 bp) and 8 (70 bp) 
and all of exon 7 (412 bp) were cloned into pCR
TM II using Invitrogen’s TA cloning 
kit. The 910 bp oAR PCR product spanning 90 bp of exon 2, all of exons 3 (118 bp), 4 
(297 bp), 5 (136 bp), 6 (130 bp) and 139 bp of exon 7 was cloned into pCR 
TM2.1.  
  The plasmids were subsequently transfected into INVαF’ competent cells 
(Stratagene, CA). Positive transformants were selected on the basis of ampicillin 
resistance and a selection of these were grown in LB broth containing ampicillin (50 
µg/µL). The ovine cDNA structures for AR, myostatin, GAPDH and the orientations 
in the plasmid were confirmed by sequencing. The myostatin and GAPDH  PCR 
products were found to be in reverse sequence in the vector. The plasmids were named 
pCR(MSTN) and pCR(GAPDH) to designate cDNA templates for ovine myostatin 
and GAPDH respectively, and pCR(ARs) and pCR(ARas) to designate cDNA 
templates for ovine AR sense and AR antisense (because the  pCR 
TM2.1 had only the 
T7 promoter, two plasmids were required; one for each orientation), respectively 
(Appendix Figures 17, 18, 19). Large scale plasmid DNA purification was carried out 
using a Qiagen Plasmid Kit.  
  The vectors pCR(MSTN), pCR(ARs) and pCR(ARas) were linearized by 
BamHI, BamHI and HincII digestion, respectively, and the cloned ovine cDNAs were 
transcribed with T7 RNA polymerase at 37°C for 1 hour using the reagents supplied 
with the Ambion's MaxiScript Kit to produce sense myostatin, sense AR and antisense 26 
 
AR, respectively. The vectors pCR(MSTN) and pCR(GAPDH) were linearized by 
DraI and EcoO109I digestion, respectively, and the cloned ovine cDNAs were 
transcribed with SP6 RNA polymerase (Ambion) at 37°C for 1 hour to produce 
antisense myostatin and antisense GAPDH. At the end of the reaction, 1 µL RNase-
free DNase I (10 U) was added and the reaction was incubated for 15 min at 37°C.  
Subsequently, all sense and antisense RNA transcripts were gel purified and the 
concentration was calculated from the OD260  after gel elution. The antisense RNA 
transcripts were labeled with Psoralen-Biotin using the BrightStar
TM Psoralen-Biotin 
Nonisotopic Labeling Kit (Ambion). Due to the abundance of GAPDH, the probe 
concentration was adjusted to generate a signal in the same range as the myostatin and 
AR signal. This adjustment was accomplished by mixing biotin-labeled and unlabeled 
GAPDH probe at a ratio of 1:25. 
2.3.2 RNase protection assay.  Forty micrograms of SP and ST muscle total 
RNA were coprecipitated with 1 ng of labeled myostatin, AR and GAPDH riboprobes 
and hybridization was performed at 42°C overnight using the protocol and the 
reagents supplied in the RPA III
TM Kit (Ambion) as described in the standard 
procedure. The next day, the mixture was treated with an RNase cocktail (0.04 U of 
RNase A and 1.5 U of RNase T1) to degrade single-stranded RNA. The protected 
fragments were precipitated, the pellets were washed once with 75% ethanol, dried, 
resuspended in 10 µL of gel-loading buffer, denatured at 95°C for 5 min, loaded onto 
a 6% polyacrylamide/8M urea denaturing gel and run at 200V for approximate one 
hour.  The RNA was then electrophoretically transferred to a positively-charged nylon 
membrane (Bright Star-Plus, Ambion) by using a mini-gel blotting apparatus 
(BioRad) and 1xTBE as transfer buffer. The transfer was carried on for 1 hour at 100 
mA, and the membrane was UV irradiated to crosslink the RNA to the nylon. The 
Ambion BrightStar BioDetection Kit was used for chemiluminescent detection of the 27 
 
protected fragments. At the end of the procedure, the membrane was exposed to X-ray 
film (Kodak) overnight at room temperature and for shorter periods (between 30 min 
and 6 hours) the following day.  
2.3.3 Quantitative analysis of myostatin and AR mRNAs. On each sample gel, 
known amounts (ranging from 52 to 0.25 pg) of in vitro synthesized myostatin and AR 
sense RNA were hybridized with an excess of labeled antisense probe (1 ng) to 
construct standard curves. The values were plotted as the log of the amount of sense 
RNA vs. the log of the intensity of the protected band in the standard curve. The 
absolute amount of the protected RNA in the muscle sample RNA was determined by 
comparing the intensity of the band to the standard curve. In some cases, the band 
density in the sample was outside the range of the standard curve. Extrapolating was 
possible because these points were close to the range of the standard curve and also, 
the points in the standard curve fitted the linear equation precisely (r
2 ranging from 
0.956 to 0.999). The amount determined using the standard curve was then corrected 
for size differences and for RNA loading. The protected fragments in the experimental 
samples differed in size from the protected fragments in the standard curve; therefore 
the difference in the amount of biotin had to be corrected. The following equation was 
used to correct for size difference:  
 
(bp)   samples   al experiment    the in fragment     protected
(bp)   curve   standard    the in fragment     protected
amount Amount × =  
To correct for variations in RNA loading, the amount corrected for size differences 
was multiplied by the ratio between the highest GAPDH amount from all gels 
(considered to correspond to the 40 µg RNA loaded into the gel) and the GAPDH 
amount from the respective lane.  28 
 
2.4 RT-PCR  
2.4.1 Construction of a heterologous competitor. The relationship between the 
initial amount A of target mRNA present in the tissue and the amount Yn of DNA 
produced after n PCR cycles can be expressed as Yn = A ⋅ (1+E)
n , where E is the 
amplification efficiency of one reaction cycle (Chelly et al. 1988). Small variations in 
reaction efficiency, therefore, translate into large differences in the amount of RT-PCR 
product generated after n cycles. These limitations in quantitative analyses can be 
overcome by parallel co-amplification of the native mRNA together with known 
amounts of an internal standard cRNA in a competitive PCR. The amplification 
efficiency should affect both templates similarly. Several designs have been used in 
quantitative RT-PCR to obtain an internal standard cRNA that has identical 
amplification efficiency to native mRNA template and is easily distinguishable from 
it. One common practice is the use of a PCR MIMIC, a heterologous internal standard 
that "mimics" the primer binding and amplification characteristics of the target 
(Gaudette & Crain 1991, Siebert & Larrick 1993), obtained by the addition of primers 
specific to gene products such as ubiquitously expressed "housekeeping" genes, like 
GAPDH (Murphy et al. 1990, Gaudette & Crain 1991).  
To quantify ovine muscle IGF-I mRNA abundance by RT-PCR, a heterologous 
competitor (MIMIC) was constructed based on the ovine GAPDH sequence obtained 
by RT-PCR using 20 nt primers homologous to ovine GAPDH sequences to which an 
additional 20 nt were appended on the 5' ends. The additional 20 nucleotides 
corresponded to the IGF-I forward and reverse primers.  These composite primers 
(Appendix Table 8) amplified a 325 bp product, including 20 bp for IGF-I at both 
ends.  29 
 
Reverse transcription was used to produce the MIMIC DNA. Using the 
Display THERMO-RT Kit, 500 µg of total ovine muscle RNA was amplified with an 
IGFGAPDH reverse primer in the reverse transcription. One µL of cDNA from the 
reverse transcription reaction was used in PCR amplification reaction using the Idaho 
Technologies Rapid Cycler and the two composite primers (IGFGAPDH forward 
primer and IGFGAPDH reverse primer). The 325 bp GAPDH MIMIC PCR product 
was cloned into pCR
TM II using Invitrogen’s TA cloning kit. The plasmid was 
subsequently transfected into INVαF’ competent cells (Stratagene, CA). Positive 
transformants were selected on the basis of ampicillin resistance and, from all positive 
colonies, 10 were grown in LB broth containing ampicillin (50 µg/µL). The 
orientation in the plasmid was checked by digestion with AluI restriction enzyme 
which has 28 restriction sites, one in the plasmid. Large scale plasmid DNA 
purification was carried out using the Qiagen Plasmid Kit. The vector was linearized 
by EcoRV digestion, and the cloned ovine cDNA was transcribed with SP6 RNA 
polymerase at 37°C for 1 hour using the reagents supplied with the Ambion's 
MaxiScript kit to create a 422 bp template containing the 325 bp MIMIC and 97 bp of 
the plasmid. At the end of the reaction, 1 µL RNase-free DNase I (10 U) was added 
and the reaction was incubated for 15 min at 37°C.  The concentration of RNA 
MIMIC was determined using spectrophotometry. 
2.4.2 Establishment and validation of quantitative RT-PCR.  To ensure a 
parallel start in all individual reactions and to increase specificity, yield and precision 
of the PCR, Zombie-Taq (Clontech) DNA polymerase was used. In the Zombie-Taq 
DNA polymerase, the polymerase activity is inhibited by the Taq antibody until the 
first denaturation step inactivates the antibody. To quantify the native IGF-I mRNA in 
different tissues, a preliminary estimation of the IGF-I cRNA start-molecule 
concentration range to be used for individual tissues was required. Initially, a broad 30 
 
range of dilutions was titrated to obtain a rough estimate of the amount of RNA 
present. This was performed by 6 titration steps ranging from 2500 to 0.025 cRNA 
start-attomoles of MIMIC in a 1:10 dilution scheme added to 600 ng total tissue RNA. 
A finer titration was then performed over a narrower range of MIMIC (24.1 to 0.01 
attomoles 1:3 dilution scheme). The final dilution series had MIMIC amounts above 
and below the equivalence point for target IGF-I in tissue RNA.   
 2.4.3 Competitive RT-PCR.  For each of the 2 muscle tissues, five RT 
reactions were performed using 600 ng of total RNA and fixed concentrations of the 
MIMIC IGF-I cRNA. Because the amount of IGF-I mRNA in muscle decreased with 
age, two different dilution series of the MIMIC IGF-I cRNA were used in order to 
keep the equivalence point close to the middle (9, 3, 1, 0.33, 0.11attomoles for the first 
18 animals and 3, 1, 0.33, 0.11, 0.04 attomoles for the remaining 18 animals). First-
strand cDNAs of target and MIMIC were generated using the Omniscript
TM RT Kit 
(Qiagen) in an Amplitron (Barnstead/Thermolyne, Dubuque, IA) thermocycler. The 
RNA, 1xRT buffer, 0.5 mM of each dNTP, 1 µM reverse primer, and 2U Omniscript 
Reverse Transcriptase were incubated for 60 min at 37°C. At the end of the reaction, 
the Omniscript Reverse Transcriptase was inactivated by heating the reaction mixture 
to 93°C for 5 min followed by rapid cooling on ice. The PCR was performed in a 
Rapid Cycler (Idaho Technologies) with 1 µL cDNA; Idaho Technologies buffer (50 
mM Tris, pH 8.3; 0.25 mM crystalline BSA; 2 mM MgCl2; and sucrose), 0.4 U Taq 
DNA polymerase (Gibco BRL), 0.2 mM dNTPs (Promega Corporation) and 0.5 µM 
each primer. The PCR used 30 cycles (0 sec at 94°C, 0 sec at 60°C, 15 sec at 75°C) 
followed by an additional 30 sec at 75°C for complete amplification of all PCR 
products. In each experiment, a negative control, with water replacing template, was 
included. 
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2.4.4 Quantification of PCR products. The ten µL PCR product was 
electrophoresed on a 5% polyacrylamide gel, which was then stained in a solution of 
0.1 µg/mL ethidium bromide (Figure 5a). The gel was scanned using a gel 
documentation and analysis system (Alpha Innotech Corp.) under UV-light. The area 
of optical densities of the target and the MIMIC peaks were quantified using the Alpha 
Innotech software (Appendix Figure 16). Because the size of the MIMIC cDNA was 
smaller than the size of the target cDNA, the decrease in the incorporation of ethidium 
bromide had to be corrected. The optical density associated with the 325 bp 
competitor (MIMIC) product was corrected by a multiplication factor corresponding 
to the bp ratio of both fragments as follows:  
length   bp   (MIMIC)   competitor
length   bp   native
  density    band density)   (band   Corrected × =  
 
A log10 transformation was used and the regression of log10 of ratio of the 
corrected MIMIC band densities to the target band densities (Y variable) against log10 
of concentration of the MIMIC (X variable) was performed. As shown in Figure 5b, 
the association was linear. When the ratio of MIMIC to target was 1 (bands densities 
equal) the amount of the target and the MIMIC was equal. To determine the amount of 
target IGF-I in the sample, the solution to the equation with Y set to 0 was transformed 
from log10 to attomoles (10
X).  32 
 
Figure 5. Competitive RT-PCR 
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Figure 5. Competitive RT-PCR.  
a) Total RNA (600 ng) was coamplified with a dilution series of IGF-I 
MIMIC cRNA (9, 3, 1, 0.33, 0.11 attomoles for the first 18 animals and 
3, 1, 0.33, 0.11, 0.04 attomoles for the rest 16 animals [lanes 2-6]).  Lane 
1 was a negative control with water replacing template. Lane 8 
represented the 100 bp DNA ladder (Life Technology, MD).  
b)  Following gel electrophoresis and staining with ethidium bromide, 
the gel was scanned and the density of each peak was integrated. After 
correcting for size differences, the log10 of the ratio of IGF-I product 
peak density to IGF-I mimic peak density was plotted against the log10 of 
the amount of IGF-I Mimic cRNA added. The quantity of IGF-I mRNA 
was determined by setting Y = 0 and transforming the solution for X 
from log10 to attomoles (10
X). 
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2.5 Statistical analyses.  
Carcass weight. 
After an initial fit of the model (1) on carcass weight, the plot of the absolute 
residuals against the fitted values for carcass weight detected heterogeneity of residual 
variance. A natural log transformation was effective in correcting this problem. The 
log of carcass weight was analyzed using the following fixed effects statistical model:  
(1)       Yijkl = µ + Ai + Sij + Pki + eijkl 
where  
Yijkl = log carcass weight from the l
th animal, within the k
th pair, of the j
th sex, in the i
th 
age class, 
µ = overall mean, 
Ai = i
th age class (i = 77d, 105d, 133d, 161d), 
Sij  = j
th sex within i
th the age class (j = ram, wether), 
Pki = k
th pair within i
th the age class (k = 1, 2,…18), 
eijkl  = error associated with ijkl
th observation, assumed to be normally  
distributed N (0, σ
2
e). 
The fixed effects model had 35 degrees of freedom: the age class effect with 3; 
the sex within age effect with 4; the pair within age effect with 14 and the error term 
with 14 degrees of freedom. The sex within age effect was evaluated using four one 
degree of freedom orthogonal contrasts that compared the log carcass weight between 
rams and wethers for each of the four age classes. 
 
SP and ST muscle weights.  
The difference between the two muscle weights within each individual was 
considered to evaluate the effect of sex on the growth of the two muscles over time. 34 
 
Because ST was much larger than SP, a natural log transformation was used to 
transform the two muscle weights to comparable scales. A new variable was created as 
the difference between the log SP and log ST muscle weights within each individual, 
DMW = (lnSP - lnST). The difference between the two muscle weights was analyzed 
using the same fixed effects statistical model (1). 
The sex effect was evaluated using four one degree of freedom orthogonal 
contrasts that compared the difference in log SP and log ST muscle weight between 
rams and wethers for each of the four age classes. 
Gene expression. 
The main objective was to compare the gene expression in two specific 
muscles. Because the two muscles were sampled from each individual, the gene 
expression in each muscle represented paired observations with respect to the 
individual. A new variable was created as the difference between mRNA 
concentration (attomoles/µg total RNA) in the two muscles for each gene studied,  
D = (SP - ST). 
The difference in gene expression in the SP and ST muscles was analyzed 
using the same fixed effects statistical model (1). 
The sex effect was evaluated using four one degree of freedom orthogonal 
contrasts that compared the difference in gene expression in the SP and ST muscles 
between rams and wethers for each of the four age classes. 
To test if there was a difference between sexes in gene expression between the two 
muscles, a hypothesis test was performed. The null hypothesis was Ho: d = 0 and the 
alternative hypothesis was Ha: d > 0 for IGF-I and AR, and Ha: d < 0 for myostatin. 
The assumptions of normality and equal variance were checked with a normal 
probability plot and a plot of the absolute values of residuals against the predicted 
values. All tests were performed for an α level of 0.05.  
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CHAPTER III 
RESULTS AND DISCUSSION 
 
Eighteen sets of twins born during the March 2002 lambing season between 
March 15
th and April 2
nd were used in this study. All the animals were slaughtered 
throughout the summer of 2002 from June 4
th to September 9
th. For a general description 
of the data, the subclass means and standard deviations for all variables in this 
experiment are presented. Additional information on individual animals is presented in 
Appendix Table 9.
 
Table 1. Carcass, semitendinosus (ST) and splenius (SP) muscle weights.   
Sex 
Number 
of 
animals 
Age 
group 
(days) 
Carcass 
weight (kg)  ST muscle (g)  SP muscle (g) 
Rams  4  77  6.58 ± 0.96  34.50 ± 10.14  3.37 ± 0.69 
Wethers  4  77  9.018 ± 2.47  51.50 ± 13.85  4.99 ± 1.50 
Rams  4  105  13.558 ± 3.15  75.02 ± 12.43  8.42 ± 2.38 
Wethers  4  105  14.178 ± 1.49  83.97 ± 5.23  7.12 ± 1.00 
Rams  6  133  19.208 ± 4.04  96.25 ± 15.89  13.20 ± 3.29 
Wethers  6  133  17.358 ± 3.07  89.82 ± 15.48  9.08 ± 1.12 
Rams  4  161  17.978 ± 2.75  99.32 ± 16.84  14.27 ± 5.61 
Wethers  4  161  18.26 ± 0.86  96.97 ± 14.39  9.75 ± 3.36 36 
 
 
 
Table 2. IGF-I, AR and myostatin mRNA concentrations (attomoles per µg RNA). 
 
 
 
 
 
 
 
 
     Attomoles / µg RNA 
Sex  Age group 
(days) 
IGF-I mRNA 
SP-ST 
AR mRNA 
SP-ST 
MSTN mRNA 
SP-ST 
Rams  77  0.11 ± 0.11  0.21 ± 0.22  -0.36 ± 0.29 
Wethers  77  0.25 ± 0.10  0.30 ± 0.16  -0.12 ± 0.46 
Rams  105  -0.05 ± 0.07  0.74 ± 0.38  -0.16 ± 0.29 
Wethers  105  -0.05 ± 0.09  0.23 ± 0.26  -0.18 ± 0.21 
Rams  133  0.16 ± 0.06  0.90 ± 0.31  -0.27 ± 0.47 
Wethers  133  -0.05 ± 0.06  0.05 ± 0.21  -0.24 ± 0.50 
Rams  161  0.16 ± 0.04  0.95 ± 0.19  0.04 ± 0.13 
Wethers  161  -0.02 ± 0.02  0.04 ± 0.19  -0.27 ± 0.28 37 
 
3.1 Carcass weight  
A plot of carcass weight data against age for the two sexes is presented in Figure 6. 
Figure 6. Carcass weight for rams and wethers across ages 
 
Wethers were heavier than rams at 77 days of age and the difference approached 
significance (p = 0.07) but no sex-related differences were found for the other age groups 
(Table 3 and Appendix Table 10). When evaluating carcass weight, the small sample size 
for each age group and the fact that the rams and the wethers in this experiment are pairs 
of twins need to be considered. Within each twin pair one individual is likely to be 
heavier than the other one especially at younger ages. Therefore the difference in carcass 
weight between the two sexes found in the first age group could be attributed to chance 
alone. Even though no statistically significant difference in carcass weight between rams 
and wethers after puberty was found, carcasses from wethers at older ages appeared to be 
fatter, in line with the report that when animals are allowed ad libitum access to a high-
energy diet, anabolic effects of hormones are sometimes observed only in body 
composition differences because control animals consume enough food to gain 
significant amounts of fat (Rosemberg et al. 1989). 
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Figure 6. Carcass weight for rams and wethers across ages. 38 
 
 
Table 3. Contrasts evaluating sex within age effect on log carcass weight. 
Model: Lg(Carcass Weight) = Age + Sex(Age) + Pair(Age) 
Contrast  DF  SS  MS  F Value  p value 
Sex within 77 days  1  0.17  0.17  3.75  0.07 
Sex within 105 days  1  <0.01  <0.01  0.17  0.69 
Sex within 133 days  1  0.02  0.02  0.64  0.44 
Sex within 161 days  1  <0.01  <0.01  0.02  0.88 
 
3.2 Semitendinosus and splenius muscle weights  
The raw data for SP and ST muscles classified by sex and age and by sex and carcass 
weight are presented in Figure 7. There was a difference in the SP muscle weight 
between rams and wethers at later ages in this experiment while the ST muscle weight 
was similar between the two sexes across all ages (Figure 7a). The same difference for 
the SP muscle weight was associated with heavier carcass weights (Figure 7b). 
The genetic similarity between twins was accounted for by the pair effect.  
     The statistical significance of the sex effect on the difference between the two 
muscles was evaluated using orthogonal contrasts (Table 4 and Appendix Table 11). No 
significant difference was found between rams and wethers for the difference in the 
weight of the two muscles at 77 days of age but the sex effect was significant at 105, 131 
and 161 days of age (p = 0.05, p = 0.04 and p = 0.02). The heavier weight of the SP 
muscle in rams relative to wethers for the same age supports the hypothesis that the 
presence of testosterone is an important factor in sexual dimorphism of SP muscle.   
 39 
 
 
  
Figure 7. Splenius and semitendinosus muscle weight for rams and wethers 
Table 4. Contrasts evaluating sex within age effect on the difference between the log of 
the two muscle weights. 
Model: Lg(SP) – Lg(ST) = Age + Sex(Age) + Pair(Age) 
Contrast  DF  SS  MS  F Value  p value 
Sex within 77 days  1  <0.01  <0.01  0.08  0.78 
Sex within 105 days  1  0.14  0.14  4.25  0.06 
Sex within 133 days  1  0.23  0.23  7.26  0.02 
Sex within 161 days  1  0.23  0.23  7.26  0.02 
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    Figure 7. a)  Splenius and semitendinosus muscle weights for rams and wethers versus age. 
b)  Splenius and semitendinosus muscle weights for rams and wethers versus  
carcass weight.40 
 
3.1 IGF-I mRNA expression  
IGF-I mRNA expression was determined using a competitive RT-PCR (Appendix 
Figures 11, 12, 13, 14). The raw data for IGF-I mRNA expression in SP and ST muscles 
classified by sex and age are presented in Figure 8.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. IGF-I mRNA levels in rams and wethers 
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Figure 8. a) IGF-I mRNA level in splenius and semitendinosus muscles in rams and   
                    wethers at different ages. 
               b) IGF-I difference between SP and ST muscles in rams and wethers at   
                   different ages.   41 
 
The IGF-I mRNA concentration was higher at 77 days and lower at later ages in 
both muscles, but for SP it was higher in rams while for ST the two sexes had similar 
concentrations at these later ages (Figure 8a). The differences in IGF-I mRNA expression 
between SP and ST muscles for rams and wethers at different ages show a similar trend 
(Figure 8b). These observations suggest that IGF-I expression is decreasing with 
increasing maturity of muscle tissue, a relation which is supported by reports that skeletal 
muscle IGF-I mRNA expression in postnatal animals decreases with increasing age 
(Dickson et al. 1991, Oldham et al. 1996).  
The statistical significance of the sex effect on the difference in IGF-I gene 
expression between the two muscles was evaluated using orthogonal contrasts (Table 5 
and Appendix Table 12). The difference in IGF-I mRNA expression between SP and ST 
was not greater in rams than in wethers at 77 or 105 days of age but it was greater at 133 
and 161 days of age (p = 0.001 and p = 0.014). These results support the hypothesis that 
the increase in splenius muscle weight in rams relative to wethers is associated with an 
increase in locally produced IGF-I in SP muscle in response to testosterone. It is not 
surprising that no difference was found between rams and wethers at 105 days of age 
which is the age when puberty is thought to occur in sheep. It is possible that some of the  
 
Table 5. Contrasts evaluating sex within age effect on the difference in IGF-I gene 
expression in the SP and ST muscles. 
Model: IGFSP – IGFST = Age + Sex(Age) + Pair(Age) 
Contrast  DF  SS  MS  F Value  p value 
Sex within 77 days  1  0.04  0.04  5.52  0.97 
Sex within 105 days  1  <0.01  <0.01  0.02  0.90 
Sex within 133 days  1  0.13  0.13  19.11  <0.01 
Sex within 161 days  1  0.06  0.06  9.82  <0.01 42 
 
 
rams had not reached puberty at this point in time or that higher levels of testosterone 
might be necessary for an effect on IGF-I gene expression.  
These results are consistent with a study of IGF-I gene expression in cattle (Pfaffl 
et al. 1998a). Insulin-like growth factor I mRNA expression was measured in two 
muscles selected because of their overproportional (m. splenius) and underproportional 
(m. gastrocnemius) growth response to testicular steroids. In bulls, higher IGF-I mRNA 
concentration was found in the m. splenius compared to m. gastrocnemius. Thus, local 
differences in IGF-I expression is one of the mediators of the differential growth of these 
muscles in intact males. 
3.2 AR mRNA expression 
AR gene expression in the two muscles showing differential growth patterns was 
measured by a ribonuclease protection assay using GAPDH to normalize AR data for 
differences in RNA loading (Appendix Figure 15). The raw data for the difference in AR 
mRNA between SP and ST muscles classified by sex and age are presented in Figure 9.  
 
Figure 9. AR mRNA levels in rams and wethers 
 
 
 
 
 
 
 
 
-0.5
0.0
0.5
1.0
1.5
49 77 105 133 161
Age, days
A
R
 
m
R
N
A
 
(
S
P
-
S
T
)
,
 
a
t
t
o
m
o
l
e
s
/
u
g
 
R
N
A Rams
wethers
 
Figure 9. AR mRNA difference between SP and ST muscles in rams and  
               wethers at different ages.   43 
 
There was similar AR mRNA expression in SP and ST muscles in the two sexes 
at 77 days (Figure 9). At later ages, the AR mRNA expression was higher in SP relative 
to ST muscle in rams, while in wethers the difference between SP and ST AR mRNA 
was about 0 suggesting that the expression level of this gene remained similar in the two 
muscles for wethers.  
The statistical significance of the sex effect on the difference in AR mRNA 
expression between the two muscles was evaluated using orthogonal contrasts (Table 6 
and Appendix Table 12). The difference in AR mRNA expression between SP and ST 
was not greater in rams than in wethers at 77 days of age but it was significantly greater 
at 105, 133 and 161 days of age (p = 0.002, p < 0.0001 and p < 0.0001).  
 
Table 6. Contrasts evaluating sex within age effect on the difference in AR gene 
expression in the SP and ST muscles. 
Model: ARSP – ARST = Age + Sex(Age) + Pair(Age) 
Contrast  DF  SS  MS  F Value  p value 
Sex within 77 days  1  0.01  0.01  0.45  0.51 
Sex within 105 days  1  0.52  0.52  17.44  <0.01 
Sex within 133 days  1  2.15  2.15  71.39  <0.01 
Sex within 161 days  1  1.65  1.65  54.98  <0.01 
 
The increased responsiveness of neck muscles to testosterone could be correlated 
with the AR level as changes in the number of receptors are a point of modulation of 
sensitivity to hormones. Divergent densities of AR in individual muscles have been 
reported previously in cattle (Sauerwein & Meyer 1989) and data on the developmental 
regulation of AR mRNA expression in three bovine muscles that differed in muscle fiber 
composition, metabolic activity and growth pattern showed a relationship between AR 44 
 
mRNA concentration and differential growth (Krieg et al. 1977). The higher AR mRNA 
concentrations in SP muscle in rams shown in this experiment are in agreement with 
those previous studies and help to explain the pronounced muscle growth in the neck of 
maturing rams. 
3.3 Myostatin mRNA expression 
The ribonuclease protection assay indicated the presence of myostatin mRNA in 
both skeletal muscles (Appendix Figure 15). The raw data for the difference in myostatin 
mRNA between SP and ST muscles classified by sex and age are presented in Figure 10. 
 
Figure 10. Myostatin mRNA levels in rams and wethers 
There was no difference between the SP and ST myostatin mRNA expression in 
rams and wethers (Figure 10).  
The statistical significance of the sex effect on the difference in myostatin mRNA 
expression between the two muscles was evaluated using orthogonal contrasts (Table 7 
and Appendix Table 12). No significant sex effect was found in the expression of 
myostatin gene in the two muscles. 
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Figure 10. Myostatin mRNA difference between SP and ST muscles 
                  in rams and wethers at different ages.   45 
 
Table 7. Contrasts evaluating sex within age effect on the difference in myostatin gene 
expression in the SP and ST muscles. 
Model: MSTNSP – MSTNST = Age + Sex(Age) + Pair(Age) 
Contrast  DF  SS  MS  F Value  p value 
Sex within 77 days  1  0.12  0.12  1.32  0.27 
Sex within 105 days  1  <0.01  <0.01  0.01  0.94 
Sex within 133 days  1  <0.01  <0.01  0.03  0.86 
Sex within 161 days  1  0.19  0.19  2.12  0.17 
 
Lower myostatin gene expression in the SP muscle in rams was expected to 
explain the increased muscle mass. The possible role of myostatin in the sexual 
dimorphic muscle growth of SP muscle can not be ruled out even if there were no 
differences in myostatin mRNA between rams and wethers. Others have reported that, 
while myostatin mRNA concentration does not differ between sexes there are different 
levels of processed myostatin expressed in male and female mice associated with 
increased body and muscle mass (McMahon et al. 2003). 
  
46 
CHAPTER IV 
CONCLUSIONS 
 
This experiment is consistent with the hypothesis that the increased splenius muscle 
mass of the neck associated with sexual maturity of rams is mediated by an increase in 
IGF-I and AR gene expression. However, the regulation of the other components of the 
IGF-I system should be studied to be able to judge the relevance of the IGF system for 
regulation of differential muscle growth. Also, the AR role in the muscle growth 
regulation should be investigated further as other genes that are regulated by this 
transcription factor could be associated with muscle growth regulation.  
There was no difference in the myostatin gene expression associated with the sexually 
dimorphic muscle growth. It would be of considerable interest to determine if there is a 
difference in the expression of processed myostatin in the sexually dimorphic muscles in 
rams and wethers.  
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APPENDIX 
 
 
Note: Table 1, 2, 3, 4, 5, 6 and 7 are presented on pages 37, 38, 40, 42, 44, 46 and 48.  
Table 8. Primer pairs and the PCR conditions. 
 
Amplified 
fragment  
Primer 
name  Primer sequence  PCR conditions 
910 bp of the 
androgen 
receptor (AR) 
gene 
AR  
  Forward 
  Reverse 
 
5’-GCC TGA TCT GTG GAG ATG AA-3’ 
5’-AGC TTG GTG AGC TGG TAG AA-3’ 
30" 94°C 
30 cycles:  0"94°C,  
                  0"55°C,  
                20"72°C 
1'72°C; 5'25°C 
2 mM MgCl2 
453 bp of the 
myostatin 
(MSTN) gene 
MSTN  
  Forward 
  Reverse 
 
5’-GCT CCT TGG AAG ACG ATG AC-3’ 
5’-CTT CTA AAA AAG GAT TCA GT-3’ 
30" 94°C 
30 cycles:  0"94°C,  
                  0"62°C,  
                20"72°C 
1'72°C; 5'25°C 
4 mM MgCl2 
556 bp of the 
GAPDH gene 
GAPDH  
  Forward 
  Reverse 
 
5’- C TGC ACC ACC AAC TGC TTA G-3’ 
5’- T TAC TCC TTG GAG GCC ATG T-3’ 
30" 94°C 
30 cycles:  0"94°C,  
                  0"55°C,  
                20"72°C 
1'72°C; 5'25°C 
2 mM MgCl2 
358 bp of the 
insulin-like 
growth factor I 
(IGF-I) gene 
IGF-I  
  Forward 
  Reverse 
 
5’-CGC ATC TCT TCT ATC TGG CC-3’ 
5’-TTG TTT CCT GCA CTC CCT CT-3’ 
30" 94°C 
30 cycles:  0"94°C,  
                  0"55°C,  
                20"72°C) 
1'72°C; 5'25°C 
4 mM MgCl2 
325 bp of the 
MIMIC IGF-I 
IGFGAPDH  
  Forward 
   
  Reverse 
 
5’-CGC ATC TCT TCT ATC TGG CCC 
TGC ACC ACC AAC TGC TTA G-3’ 
5’-TTG TTT CCT GCA CTC CCT CTT 
TAC TCC TTG GAG GCC ATG T-3’ 
30" 94°C 
30 cycles:  0"94°C,  
                  0"58°C,  
                20"72°C) 
1'72°C; 5'25°C 
2 mM MgCl2 
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Table 9. Animal number, pair and animal id, sex and age class for experimental animals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Animal 
Number  Pair ID  Animal ID  Sex  Age class 
(days) 
1 4  P2097  Wether  77 
2 4  P2098  Ram  77 
3 5  P2099  Ram  77 
4 5  P2100  Wether  77 
5 12  P2117  Ram  77 
6 12  P2118  Wether  77 
7 14  P2121  Wether  77 
8 14  P2122  Ram  77 
9 1  P2091  Wether 105 
10 1  P2092  Ram  105 
11 6  P2101  Wether  105 
12 6  P2102  Ram  105 
13 16  P2125  Wether  105 
14 16  P2126 Ram  105 
15 18  P2129 Ram  105 
16 18  P2130  Wether  105 
17 2  P2093  Ram  133 
18 2  P2094  Wether  133 
19 3  P2095  Wether  133 
20 3  P2096  Ram  133 
21 8  P2105  Wether  133 
22 8  P2106  Ram  133 
23 10  P2109 Ram  133 
24 10  P2110  Wether  133 
25 15  P2123  Wether  133 
26 15  P2124 Ram  133 
27 17  P2127 Ram  133 
28 17  P2128  Wether  133 
29 9  P2107  Wether  161 
30 9  P2108  Ram  161 
31 13  P2119 Ram  161 
32 13  P2120  Wether  161 
33 19  P2131  Wether  161 
34 19  P2132 Ram  161 
35 20  P2135  Wether  161 
36 20  P2136 Ram  161 49 
 
Table 10. The output of analysis of variance performed with the model:  
               Yijkl = µ + Ai +  Sij + Pki + eijkl for log carcass weight (kg). For a    
               description of the model, see Materials and Methods. 
 
                                                       Sum of 
       Source                      DF         Squares      Mean Square     F Value    Pr > F 
       Model                       21      4.93740178      0.23511437       5.22        0.0013 
       Error                         14      0.63006986      0.04500499 
       Corrected Total        35      5.56747164 
 
 
                     R-Square     Coeff Var      Root MSE    lgcarcasswt Mean 
                     0.886830      8.049044      0.212144            2.635640 
 
 
       Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
       days                            3      4.31363943      1.43787981      31.95      <.0001 
       sex(days)                    4      0.20617721      0.05154430       1.15       0.3757 
       pair(days)                  14     0.41758513      0.02982751       0.66       0.7744 
 
 
       Contrast                    DF     Contrast SS     Mean Square    F Value    Pr > F 
       sex within time1          1      0.16864803      0.16864803        3.75       0.0734 
       sex within time2          1      0.00763146      0.00763146        0.17       0.6867 
       sex within time3          1      0.02880940      0.02880940        0.64       0.4370 
       sex within time4          1      0.00108831      0.00108831        0.02       0.8786 
 
 
 
 
Table 11. The output of analysis of variance performed with the model:  
              DMWijkl = µ + Ai + Sij + Pki + eijkl for the difference between 
              the log of the two muscle weights (g). For a description of the model,  
              see Materials and Methods.   
 
                                                      Sum of 
       Source                      DF         Squares     Mean Square    F Value    Pr > F 
       Model                       21      1.58126808      0.07529848       2.33      0.0542 
       Error                         14      0.45324248      0.03237446 
       Corrected Total        35      2.03451056 
 
 
                      R-Square     Coeff Var      Root MSE    lgspl_st Mean 
                      0.777223     -8.068059      0.179929        -2.230141 
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Table 11 (Continued). 
 
       Source                      DF     Type III SS      Mean Square    F Value    Pr > F 
       days                            3      0.29076233      0.09692078       2.99        0.0667 
       sex(days)                    4      0.61014616      0.15253654       4.71        0.0128 
       pair(days)                  14     0.68035959      0.04859711       1.50        0.2284 
 
 
       Contrast                    DF     Contrast SS     Mean Square    F Value    Pr > F 
       sex within time1          1      0.00256680      0.00256680       0.08        0.7824 
       sex within time2          1      0.13761179      0.13761179       4.25        0.0583 
       sex within time3          1      0.23498642      0.23498642       7.26        0.0175 
       sex within time4          1      0.23498115      0.23498115       7.26        0.0175 
 
 
 
 
Table 12. The output of analysis of variance performed with the model:  
              Dijkl = µ + Ai + Sij + Pki + eijkl for the difference in gene expression 
              in the SP and ST muscles (attomoles per µg RNA). For a  
description of the model, see Materials and Methods.   
 
IGF-Isplenius - IGF-Isemitendinosus 
 
                                                       Sum of 
       Source                      DF         Squares      Mean Square    F Value    Pr > F 
       Model                       21      0.50443750      0.02402083       3.64        0.0081 
       Error                         14      0.09236250      0.00659732 
       Corrected Total        35      0.59680000 
 
 
                       R-Square     Coeff Var      Root MSE    Isp_st Mean 
                       0.845237      128.2483      0.081224       0.063333 
 
 
       Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
       days                            3      0.21527083      0.07175694      10.88       0.0006 
       sex(days)                    4      0.22743750      0.05685938       8.62        0.0010 
       pair(days)                 14      0.06172917      0.00440923       0.67        0.7698 
 
 
       Contrast                    DF     Contrast SS     Mean Square    F Value    Pr > F 
       sex within time1          1      0.03645000      0.03645000       5.52        0.9666 
       sex within time2          1      0.00011250      0.00011250       0.02        0.8980 
       sex within time3          1      0.12607500      0.12607500      19.11       0.0006 
       sex within time4          1      0.06480000      0.06480000       9.82        0.0073 
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Table 12 (Continued). 
 
ARsplenius - ARsemitendinosus 
 
                                                        Sum of 
       Source                      DF         Squares     Mean Square     F Value    Pr > F 
       Model                       21      6.04474722      0.28784511       9.56       <.0001 
       Error                         14      0.42174167      0.03012440 
       Corrected Total        35      6.46648889 
 
                       R-Square     Coeff Var      Root MSE    Asp_st Mean 
                       0.934780      39.95075      0.173564       0.434444 
 
       Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
       days                            3      0.32839722      0.10946574       3.63        0.0397 
       sex(days)                    4      4.34565833      1.08641458      36.06       <.0001 
       pair(days)                 14      1.37069167      0.09790655       3.25        0.0175 
 
       Contrast                    DF     Contrast SS     Mean Square    F Value    Pr > F 
       sex within time1         1      0.01361250      0.01361250         0.45       0.5124 
       sex within time2         1      0.52531250      0.52531250        17.44      0.0009 
       sex within time3         1      2.15053333      2.15053333        71.39      <.0001 
       sex within time4         1      1.65620000      1.65620000        54.98      <.0001 
 
 
MSTNsplenius - MSTNsemitendinosus 
 
                                                        Sum of 
       Source                      DF         Squares     Mean Square    F Value    Pr > F 
       Model                       21      3.12129722      0.14863320       1.67       0.1643 
       Error                         14      1.24862500      0.08918750 
       Corrected Total        35      4.36992222 
 
                       R-Square     Coeff Var      Root MSE    Msp_st Mean 
                       0.714268     -147.2759      0.298643      -0.202778 
 
       Source                      DF     Type III SS     Mean Square    F Value    Pr > F 
       days                           3      0.11588056      0.03862685       0.43        0.7326 
       sex(days)                   4      0.30987500      0.07746875       0.87        0.5068 
       pair(days)                14      2.69554167      0.19253869       2.16        0.0811 
 
       Contrast                    DF     Contrast SS     Mean Square    F Value    Pr > F 
       sex within time1         1      0.11761250      0.11761250        1.32        0.2701 
       sex within time2         1      0.00045000      0.00045000        0.01        0.9444 
       sex within time3         1      0.00270000      0.00270000        0.03        0.8644 
       sex within time4         1      0.18911250      0.18911250        2.12        0.1674 
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Figure 11. Quantitative RT-PCR analyses for IGF-I mRNA in splenius muscle 
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Figure 11. Quantitative RT-PCR analyses for insulin-like growth factor I 
(IGF-I) mRNA abundance in ovine splenius muscle. Gel electrophoresis of PCR 
products for wild-type and mimic (358 and 325 bp, respectively) DNA templates. 
Lane 1 to 5: native mRNA spiked with decreasing mimic cRNA concentrations (9, 
3, 1, 0.33, 0.11 attomoles). The letters a to s represent animals 1 to 18. 
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Figure 12. Quantitative RT-PCR analyses for IGF-I mRNA in semitendinosus muscle 
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Figure 12. Quantitative RT-PCR analyses for insulin-like growth factor I (IGF-I) 
mRNA abundance in ovine semitendinosus muscle. Gel electrophoresis of PCR 
products for wild-type and mimic (358 and 325 bp, respectively) DNA templates. Lane 
1 to 5: native mRNA spiked with decreasing mimic cRNA concentrations (9, 3, 1, 0.33, 
0.11 attomoles). The letters a to s represent animals 1 to 18. 54 
 
 Figure 14. Quantitative RT-PCR analyses for IGF-I mRNA in splenius 
muscle
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Figure 13. Quantitative RT-PCR analyses for insulin-like growth factor I (IGF-I) mRNA 
abundance in ovine splenius muscle. Gel electrophoresis of PCR products for wild-type and 
mimic (358 and 325 bp, respectively) DNA templates. Lane 1 to 5: native mRNA spiked with 
decreasing mimic cRNA concentrations (3, 1, 0.33, 0.11, 0.04 attomoles). The letters a to s 
represent animals 19 to 36. 55 
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Figure 14. Quantitative RT-PCR analyses for insulin-like growth factor I (IGF-I) mRNA 
abundance in ovine semitendinosus muscle. Gel electrophoresis of PCR products for wild-
type and mimic (358 and 325 bp, respectively) DNA templates. Lane 1 to 5: native mRNA 
spiked with decreasing mimic cRNA concentrations (3, 1, 0.33, 0.11, 0.04 attomoles). The 
letters a to s represent animals 19 to 36. 56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Quantitative analises of myostatin and AR in splenius and semitendinosus muscles 
 
Figure 15. Quantitative analyses of myostatin (MSTN) and androgen receptor (AR) 
mRNA in ovine tissues using GAPDH as an internal control. The standard curve was 
constructed by hybridizing 1 ng of MSTN, AR and GAPDH antisense probe to known 
amounts, ranging from 52 to 0.25 pg of sense MSTN, AR and GAPDH cRNA, 
respectively. Lane SP and ST represents the hybridization of 1 ng MSTN, AR and 
GAPDH antisense probe with 40 ug semitendinosus and splenius muscle RNA. Lane 
CM represents the RNA molecular weight marker (Century Marker, Ambion). The 
numbers 1 to 36 represent the animals. The exposure time varied between 30 minutes 
and 6 hours. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 57 
 
 
 
 
 
 
 
                  Standard curve               1            2            3    a 
    a)   28   14    7     3     2    1     SP  ST  SP  ST   SP  ST  CM 
            
 
 
            Standard curve           5            6            4    a       3       a              
 b)    52   26   13    7     3    SP  ST   SP  ST   SP  ST   SP   ST CM 
       
 
 
 
            Standard curve           7            8            9     a     10      a              
c)   28    14    7     3     2     SP  ST   SP  ST   SP  ST   SP   ST CM 
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Figure 15 (Continued) 
 
 
 
 
 
           Standard curve            11           12          13   a     14       a            
 d)    4    2     1    0.5  0.25  SP  ST   SP  ST   SP  ST   SP   ST CM 
       
 
 
               Standard curve             15          16          17   a      18      a        
  e)      12    6     3    1.5  0.5    SP  ST   SP  ST   SP  ST   SP   ST  
       
 
          Standard curve              19           20          21    a      22      a          
  f)  18   12    8    5.3  3.6    SP  ST    SP  ST    SP  ST   SP   ST CM 
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Figure 15 (Continued) 
 
 
 
 
 
 
 
           Standard curve               23           24            25   a       26     a          
 g)   18    12    8    5.3   3.6    SP  ST    SP  ST    SP  ST    SP   ST  
       
 
 
           Standard curve               27           28            29   a       30      a         
 h)   18    12    8    5.3   3.6    SP  ST    SP  ST    SP  ST    SP   ST  
        
 
 
           Standard curve              31          32          33     a      34       a           
 i)  18   12     8    5.3   3.6    SP  ST   SP  ST    SP  ST    SP   ST  
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Figure 15 (Continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                     Standard curve                   35   a a      36   a                    
 j)  CM    18    12     8      5.3   3.6     SP   ST     SP   ST    
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Figure 16. Quantification of optical densities of IGF-I target and MIMIC peaks using the Alpha 
Innotech software 
Figure 16. Quantification of optical densities of the insulin-like growth factor I (IGF-
I) target and the MIMIC peaks using the Alpha Innotech software. 
a) Using the picture of the gel, the number of lanes is specified and the placement of 
the template is adjusted so that it coincides with the positions of the lanes on the 
image. Also, the Scan Width (the area in which the pixel density actually is measured) 
is specified. 
b) Using the Scan command, the density within the Scan Width of each lane is 
measured. The image is redisplayed in a smaller window in the upper left of the 
screen and the graphs of each lane are displayed on the right. The peaks on the graph 
correspond to the bands in a lane. 
c) One way to quantify the band in a lane is to use the Auto Peak command, which 
automatically identifies the peaks, based on the parameters defined. The information 
associated with the peaks is displayed in the data table below the image. The value 
that we used was "Area" which represents the integrated density of each peak (in total 
pixel value).  
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Figure 17. pCR (MSTN) 
 
 
 
Figure 17. pCR (MSTN) 
The plasmid was composed of a 3.95 kb pCR II vector (Invitrogen, CA) and 
a 453 bp PCR product insert (myostatin) which was inserted in inverse 
orientation into the vector.  64 
 
Figure 18. pCR (GAPDH)
 
 
 
Figure 18. pCR (GAPDH) 
The plasmid was composed of a 3.95 kb pCR II vector (Invitrogen, CA) and a 556 
bp PCR product insert (GAPDH) which was inserted in inverse orientation into the 
vector.  
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Figure 19. pCR(ARs) and pCR(ARas)  
 
 
 
 
Figure 19. pCR(ARs) and pCR(ARas) 
The plasmids were composed of a 3.9 kb pCR 2.1 vector (Invitrogen, CA) 
and a 910 bp PCR product insert (androgen receptor). Clone 5 contained the 
insert in direct orientation into the vector and clone 9 contained the insert in 
inverse orientation into the vector.  
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